Relevance: Multiparametric MRI (mpMRI) is one of the main methods for diagnosing prostate cancer (PCa). Although mpMRI has been adopted into routine urological and oncological practice in a few short years, there are conflicting views on the timing of mpMRI. The purpose was to study the diagnostic value and role of mpMRI at the stages of diagnosis of prostate cancer. Methods: The article reviews the literature on the use of mpMRI in diagnosing prostate cancer in the framework of traditional clinical approaches. Results: current national guidelines in Europe emphasize the value of mpMRI in diagnosing patients with suspected PCa. The rationale for using mpMRI in selecting patients with suspected PCa who should and should not be biopsied and selecting areas of the prostate for biopsy is compelling. The evidence base, including level 1 studies, is overwhelming, as are arguments for patient benefit in avoiding biopsy or overdiagnosis of clinically insignificant cancer. Conclusion: Patients considering biopsy start to realize that mpMRI imaging can avoid biopsy in some cases and make it more targeted in others. For obvious reasons, these patients will seek to avoid the risk of biopsy or minimize the risk with fewer biopsy specimens. Switching from “standard” SB to TB judiciously and selectively augmented with BD using a two-stage risk assessment offers the best compromise to reduce biopsy rates and reduce overdiagnosis of cnPCa while minimizing the chances of missing clinically significant cancer. Evidence that it is possible to avoid SB altogether, even in the era of mpMRI before biopsy, is weak. This provides grounds for searching for new methods for diagnosing clinically significant cancer using mpMRI
Relevance: Multiparametric MRI (mpMRI) is one of the primary methods for diagnosing prostate cancer (PCa). Although mpMRI has been adopted into routine urological and oncological practice in a few short years, there are conflicting views on the timing of mpMRI.The purpose was to study the diagnostic value and role of mpMRI at the prostate cancer diagnosis stages. Methods:The article reviews the literature on the use of mpMRI in diagnosing prostate cancer in the framework of traditional clinical approaches.Results: Decisions to perform a biopsy should primarily be based on mpMRI results preferring not to biopsy on "negative" tests (any/ all PIRADS 2 or less) and targeting on PI-RADS 4 or 5. Some "negative" studies and most PI-RADS 3 lesions require a second assessment, including clinical (e.g., age, DRE, family history) and biochemical (PSA density and rate of change) parameters to define whether systematic biopsy (SB) is indicated alone or with additional targeting for low-grade PI-RADS lesions.Conclusion: Patients considering biopsy realize that mpMRI imaging can avoid biopsy in some cases and make it more targeted in others. For obvious reasons, these patients will seek to avoid the risk of biopsy or minimize the risk with fewer biopsy specimens. For example, switching from "standard" SB to target biopsy judiciously and selectively augmented with BD using a two-stage risk assessment offers the best compromise to reduce biopsy rates and reduce overdiagnosis of cnPCa while minimizing the chances of missing clinically significant cancer. Evidence that it is possible to avoid SB alto-gether, even in the era of mpMRI before biopsy, is weak. Finally, it provides grounds for searching for new methods for diagnosing clinically significant cancer using mpMRI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.